WP
BMY icon

Westmount Partners’s Bristol-Myers Squibb BMY Stock Holding History

Westmount Partners’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$587K Sell
10,185
-182
-2% -$10.5K 0.13% 133
2026
Q1 		$629K Buy
10,367
+11
+0.1% +$641 0.15% 119
2025
Q4 		$559K Sell
10,356
-52
-0.5% -$2.5K 0.14% 122
2025
Q3 		$494K Buy
10,408
+13
+0.1% +$607 0.13% 137
2025
Q2 		$481K Buy
10,395
+11
+0.1% +$540 0.13% 130
2025
Q1 		$633K Buy
10,384
+9
+0.1% +$525 0.19% 107
2024
Q4 		$587K Buy
10,375
+10
+0.1% +$559 0.18% 105
2024
Q3 		$536K Sell
10,365
-100
-1% -$4.69K 0.16% 109
2024
Q2 		$432K Buy
10,465
+123
+1% +$5.5K 0.14% 123
2024
Q1 		$561K Sell
10,342
-190
-2% -$9.68K 0.2% 104
2023
Q4 		$540K Sell
10,532
-1,254
-11% -$65.8K 0.22% 98
2023
Q3 		$684K Buy
11,786
+679
+6% +$41.6K 0.3% 79
2023
Q2 		$710K Buy
11,107
+277
+3% +$18.6K 0.31% 69
2023
Q1 		$751K Buy
10,830
+8
+0.1% +$564 0.35% 66
2022
Q4 		$779K Buy
+10,822
New +$816K 0.4% 55

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Westmount Partners's BMY Position: Q2 2026 in Review

Westmount Partners reduced its Bristol-Myers Squibb (BMY) stake by 1.8% in Q2 2026, selling an estimated $10.5K and leaving 10,185 shares worth $587K. The position accounts for 0.13% of the portfolio, ranked #133.

Westmount Partners first reported a position in BMY in Q4 2022 and has held it in 15 quarters since. The position peaked at $779K in Q4 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Westmount Partners held 10,185 shares of Bristol-Myers Squibb worth $587K as of Q2 2026.
  • Westmount Partners sold 182 Bristol-Myers Squibb shares in Q2 2026, an estimated $10.5K.
  • Bristol-Myers Squibb made up 0.13% of Westmount Partners's portfolio in Q2 2026, its #133 holding.
  • Westmount Partners first reported a position in Bristol-Myers Squibb in Q4 2022 and has held it in 15 quarters since.
  • Westmount Partners's Bristol-Myers Squibb position peaked at $779K in Q4 2022.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Westmount Partners's 13F filing for Q2 2026, filed 7 Jul 2026.